Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more
Initiator Pharma A/S (INIT) - Total Liabilities
Latest total liabilities as of September 2025: Skr4.37 Million SEK
Based on the latest financial reports, Initiator Pharma A/S (INIT) has total liabilities worth Skr4.37 Million SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Initiator Pharma A/S - Total Liabilities Trend (2016–2024)
This chart illustrates how Initiator Pharma A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Initiator Pharma A/S Competitors by Total Liabilities
The table below lists competitors of Initiator Pharma A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cheil Grinding
KO:001560
|
Korea | ₩12.90 Billion |
|
FRENF
PINK:FRENF
|
USA | $21.74 Trillion |
|
EXA E&C Inc
KQ:054940
|
Korea | ₩72.04 Billion |
|
Houston American Energy Corporation
NYSE MKT:HUSA
|
USA | $12.34 Million |
|
Mawana Sugars Limited
NSE:MAWANASUG
|
India | ₹1.08 Billion |
|
Southern Cross Media Group Limited
PINK:SOUTF
|
USA | $35.51 Million |
|
Yoong Onn Corporation Bhd
KLSE:5159
|
Malaysia | RM65.66 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Initiator Pharma A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Initiator Pharma A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Initiator Pharma A/S (2016–2024)
The table below shows the annual total liabilities of Initiator Pharma A/S from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr510.00K | -97.26% |
| 2023-12-31 | Skr18.62 Million | +30.04% |
| 2022-12-31 | Skr14.32 Million | -23.44% |
| 2021-12-31 | Skr18.71 Million | +1466.75% |
| 2020-12-31 | Skr1.19 Million | -21.96% |
| 2019-12-31 | Skr1.53 Million | +101.85% |
| 2018-12-31 | Skr758.00K | -77.26% |
| 2017-12-31 | Skr3.33 Million | +256.96% |
| 2016-12-31 | Skr934.00K | -- |